Glycyrrhizin Inhibits SARS-CoV-2 Entry into Cells by Targeting ACE2

Coronavirus Disease 2019 (COVID-19) is a highly infectious and pathogenic disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Early in this epidemic, the herbal formulas used in traditional Chinese medicine (TCM) were widely used for the treatment of COVID-19 in China. According to Venn diagram analysis, we found that Glycyrrhizae Radix et Rhizoma is a frequent herb in TCM formulas against COVID-19. The extract of Glycyrrhizae Radix et Rhizoma exhibits an anti-SARS-CoV-2 replication activity in vitro, but its pharmacological mechanism remains unclear. We here demonstrate that glycyrrhizin, the main active ingredient of Glycyrrhizae Radix et Rhizoma, prevents the coronavirus from entering cells by targeting angiotensin-converting enzyme 2 (ACE2). Glycyrrhizin inhibited the binding of the spike protein of the SARS-CoV-2 to ACE2 in our Western blot-based assay. The following bulk RNA-seq analysis showed that glycyrrhizin down-regulated ACE2 expression in vitro which was further confirmed by Western blot and quantitative PCR. Together, we believe that glycyrrhizin inhibits SARS-CoV-2 entry into cells by targeting ACE2.

[1]  Y. Liu,et al.  Chrysin Ameliorates Influenza Virus Infection in the Upper Airways by Repressing Virus-Induced Cell Cycle Arrest and Mitochondria-Dependent Apoptosis , 2022, Frontiers in Immunology.

[2]  Saliha Majdoul,et al.  Lessons in self-defence: inhibition of virus entry by intrinsic immunity , 2021, Nature Reviews Immunology.

[3]  M. Farzan,et al.  Mechanisms of SARS-CoV-2 entry into cells , 2021, Nature reviews. Molecular cell biology.

[4]  Jianwei Wang,et al.  Genome-wide CRISPR activation screen identifies candidate receptors for SARS-CoV-2 entry , 2021, Science China Life Sciences.

[5]  Hu-dan Pan,et al.  Integrated Molecular Docking with Network Pharmacology to Reveal the Molecular Mechanism of Simiao Powder in the Treatment of Acute Gouty Arthritis , 2021, Evidence-based complementary and alternative medicine : eCAM.

[6]  O. Witzke,et al.  Glycyrrhizin Effectively Inhibits SARS-CoV-2 Replication by Inhibiting the Viral Main Protease , 2021, Viruses.

[7]  J. Youn,et al.  Traditional Chinese Medicine (TCM) in the treatment of COVID-19 and other viral infections: Efficacies and mechanisms , 2021, Pharmacology & Therapeutics.

[8]  S. Agarwal,et al.  COVID-19: Characteristics and Therapeutics , 2021, Cells.

[9]  Yanhong Zhang,et al.  HDL-scavenger receptor B type 1 facilitates SARS-CoV-2 entry , 2020, Nature Metabolism.

[10]  O. Herrera-Calderón,et al.  Uncaria tomentosa (cat’s claw): a promising herbal medicine against SARS-CoV-2/ACE-2 junction and SARS-CoV-2 spike protein based on molecular modeling , 2020, Journal of biomolecular structure & dynamics.

[11]  A. Helenius,et al.  Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity , 2020, Science.

[12]  Hong Chen,et al.  Kidney injury molecule-1 is a potential receptor for SARS-CoV-2 , 2020, bioRxiv.

[13]  Yan Wang,et al.  Tissue distributions of antiviral drugs affect their capabilities of reducing viral loads in COVID-19 treatment , 2020, European Journal of Pharmacology.

[14]  J. Dye,et al.  Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2 , 2020, Science.

[15]  Sharon J Peacock,et al.  Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. , 2020, JAMA.

[16]  Yi Wang,et al.  Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial , 2020, The Lancet.

[17]  Hualiang Jiang,et al.  Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors , 2020, Nature.

[18]  Harapan Harapan,et al.  Coronavirus disease 2019 (COVID-19): A literature review , 2020, Journal of Infection and Public Health.

[19]  Sharon Einav,et al.  A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19 , 2020, Journal of Critical Care.

[20]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[21]  Ai-Hua Zhang,et al.  Traditional Chinese medicine for COVID-19 treatment , 2020, Pharmacological Research.

[22]  Jun Li,et al.  Data mining and systematic pharmacology to reveal the mechanisms of traditional Chinese medicine in Mycoplasma pneumoniae pneumonia treatment. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[23]  E. Holmes,et al.  A new coronavirus associated with human respiratory disease in China , 2020, Nature.

[24]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[25]  G. Leung,et al.  Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study , 2020, The Lancet.

[26]  E. Holmes,et al.  Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding , 2020, The Lancet.

[27]  Z. Memish,et al.  The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, China , 2020, International Journal of Infectious Diseases.

[28]  N. Hirayama.  Docking simulations between drugs and HLA molecules associated with idiosyncratic drug toxicity. , 2017, Drug metabolism and pharmacokinetics.

[29]  Billy Tsai,et al.  EMC1-dependent stabilization drives membrane penetration of a partially destabilized non-enveloped virus , 2016, eLife.

[30]  H. Shu,et al.  FoxO1 Negatively Regulates Cellular Antiviral Response by Promoting Degradation of IRF3* , 2013, The Journal of Biological Chemistry.

[31]  M. Marsh,et al.  Rab7A Is Required for Efficient Production of Infectious HIV-1 , 2011, PLoS pathogens.

[32]  D. Ann,et al.  The early autophagic pathway is activated by hepatitis B virus and required for viral DNA replication , 2010, Proceedings of the National Academy of Sciences.

[33]  J. Ziebuhr,et al.  Conservation of substrate specificities among coronavirus main proteases. , 2002, The Journal of general virology.

[34]  T. Hishinuma,et al.  Determination of serum concentrations of glycyrrhizin in humans by semi-micro high-performance liquid chromatography after administration of a therapeutic dose. , 2000, Biological & pharmaceutical bulletin.